Methods for the treatment of patients with cancer and preferably with a hematological disease include the analysis of gene expression profiles and / or molecular markers of a patient to determine the status and / or prognosis of the patient. Methods are provided to analyze whether a non-recurrent...
Introduction Chronic lymphocytic leukemia (CLL) is a clinically and genetically heterogenous disease. Genomic studies have deciphered the pathogenesis of CLL and has allowed the identification of prognostic and predictive biomarkers. During the last decade, the treatment options for CLL have expanded ...
Leukemia: A Brief Overview Infocenter articles Chronic myeloid leukemia Acute myeloid leukemia prognosis Leukemia prognosis Leukemia survival rate Down syndrome prognosis View more Facts About Childhood Leukemia Acute Lymphocytic Leukemia in Children: Conventional Treatment Interferon Treatment For ...
TREATMENT OF CHRONIC LEUKEMIA We report a case of chronic myelogenous leukemia (CML) with marked thrombocytosis. The patient was a 68-year-old woman who showed marked thrombocytosis (> ... WC Moloney 被引量: 2发表: 1969年 A clinical staging system for chronic lymphocytic leukemia. Prognostic ...
The level of sIL-2R might be an indicator of the initiation of therapy for indolent ATL. Keywords: adult T-cell leukemia/lymphoma; smoldering-type; chronic-type; iATL-PI1. Introduction Adult T-cell leukemia/lymphoma (ATL) is an aggressive peripheral T-cell lymphoma associated with human T-...
Membrane-bound CD200 is overexpressed in chronic lymphocytic leukemia (CLL), and there is some evidence that its soluble ectodomain (sCD200) could also be involved in the pathophysiology and the disease. However, very little is known about sCD200’s prognostic significance. sCD200 was tested at...
Through the European Research Initiative on chronic lymphocytic leukemia (CLL) (ERIC), we screened 3490 patients with CLL for mutations within the NOTCH1 (n=3334), SF3B1 (n=2322), TP53 (n=2309), MYD88 (n=1080) and BIRC3 (n=919) genes, mainly at diagnosis
byWhitehead Institute for Biomedical Research Researchers at Whitehead Institute and Children's Hospital Boston have identified a protein, called Musashi 2, that is predictive of prognosis in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) patients. ...
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients. ...
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world. Alterations in microRNAs (miRNAs) expression have been proposed to play a role in CLL pathogenesis. Dicer and Drosha are the main regulators of miRNA biogenesis, and deregulation of their expression has been indic...